Bioamber (BIOA) Downgraded by ValuEngine

ValuEngine lowered shares of Bioamber (NYSE:BIOA) from a sell rating to a strong sell rating in a report issued on Friday.

Several other brokerages have also issued reports on BIOA. HC Wainwright reaffirmed a buy rating and set a $12.00 price target on shares of Bioamber in a research note on Wednesday, November 8th. Cowen reaffirmed a hold rating and set a $1.00 price target on shares of Bioamber in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. Bioamber presently has an average rating of Hold and an average price target of $6.50.

Shares of Bioamber (NYSE BIOA) traded down $0.02 on Friday, hitting $0.42. The stock had a trading volume of 938,700 shares, compared to its average volume of 948,388. The company has a current ratio of 1.08, a quick ratio of 0.75 and a debt-to-equity ratio of 0.24. Bioamber has a twelve month low of $0.32 and a twelve month high of $6.24.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Robecosam AG increased its holdings in Bioamber by 82.9% in the third quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after purchasing an additional 670,000 shares during the last quarter. FMR LLC increased its holdings in Bioamber by 1.9% in the second quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock valued at $3,495,000 after purchasing an additional 25,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in Bioamber by 9.9% in the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 27,278 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Bioamber by 336.2% in the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after purchasing an additional 41,701 shares during the last quarter. Finally, TD Asset Management Inc. bought a new stake in Bioamber in the second quarter valued at about $977,000. Institutional investors and hedge funds own 29.97% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Bioamber (BIOA) Downgraded by ValuEngine” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.com-unik.info/2017/12/04/bioamber-bioa-downgraded-by-valuengine.html.

Bioamber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about Bioamber Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioamber Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit